

To the Marketing Department Pharma Bio Serv Inc INDUSTRIAL ZONE STREET 1 LOT 14 DORADO, PR 00646 USA

September 20, 2025

Pharma Bio Serv Inc TOP Rated in the US Consulting & Services Ranking

Dear Sir or Madam,

at RealRate we have just published the 2025 US Consulting & Services ranking. I am happy to inform you that Pharma Bio Serv Inc has been TOP Rated at rank 3 out of 24.

Overall, 24 US companies were analyzed with respect to their financial strength. The complete rating is published at https://www.realrate.ai/rankings. Your individual rating report, showing your strengths compared to your competitors is attached.





RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

I took the liberty of sending an identical letter to the CEO. Please feel free to book a short video call with me: https://calendly.com/holger-bartel

Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.

2040 Martin Ave., Santa Clara, California 95050, USA

Via email to: holger.bartel@realrate.ai

We subscribe to the Consulting & Services RealRate rating for Pharma Bio Serv Inc. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.





RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Pharma Bio Serv Inc (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item 2025 US Consulting & Services RealRate rating seal for Pharma Bio Serv Inc

Amount **USD 9,900** Order no. 2025-0001304161

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address

Company name
Street address
Department
City
Phone number
State / provice
Email address

ZIP code Country

Shipping address

The electronic RealRate rating seal and the invoice will be sent to Delivery email


Pharma Bio Serv Inc	
Date, location, name	



CONSULTING & SERVICES 2025



Pharma Bio Serv Inc Rank 3 of 24





CONSULTING & SERVICES 2025



Pharma Bio Serv Inc Rank 3 of 24



The relative strengths and weaknesses of Pharma Bio Serv Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pharma Bio Serv Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Pharma Bio Serv Inc is the variable Cost of Revenues, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 215%, being 80% points above the market average of 136%.

Input Variable	Value in 1000 USD
Assets, Current	15,699
Assets, Noncurrent	395
Cost of Revenues	6,993
General And Administrative Expense	3,804
Intangible Assets	0
Labor Expense	0
Liabilities, Current	1,887
Liabilities, Non-Current	29
Operating Lease Assets	199
Other Assets	0
Other Compr. Net Income	52
Other Expenses	22
Other Liabilities	661
Other Net Income	0
Other Revenues	10,041
Revenue from Contract with Customer	0
Revenue from Reimbursement	0

Output Variable	Value in 1000 USD
Assets	16,292
Liabilities	2,577
Expenses	10,819
Revenues	10,041
Stockholders Equity	13,715
Net Income	-778
Comprehensive Net Income	-726
ECR before LimitedLiability	125%
Economic Capital Ratio	215%

